PlainPharmaWatch

CMS Open Payments · Program Year 2024

Veloxis Pharmaceuticals, Inc.

Veloxis Pharmaceuticals, Inc. reported $1,594,463.02 in payments to 766 physicians and teaching hospitals across 822 transactions.

See the rankings → How this is sourced
$1.6M
Total payments
822
Transactions
766
Recipients
−$97.5K
General Payments vs PY2023

Veloxis Pharmaceuticals, Inc. reported $1,594,463.02 in payments to 766 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #511 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $2.1K per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Veloxis Pharmaceuticals, Inc. pairs above-median payment volume with an unusually diversified payment pattern across a wide recipient base.

#511
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Veloxis Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $97.5K (−52.2%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: VELOXIS PHARMACEUTICALS, INC.PY2023: VELOXIS PHARMACEUTICALS, INC.PY2024: Veloxis Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$186.7KPY2024$89.2K
PY2023
$186,725.63
PY2024
$89,196.03

How Veloxis Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Veloxis Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,594,463 Top 26% higher than 74% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Veloxis Pharmaceuticals, Inc.

Averaging $1.9K per transaction and $2.1K per recipient, Veloxis Pharmaceuticals, Inc.'s Program Year 2024 total comes to $1,594,463.02 across 822 transactions and 766 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #511 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 6 general-payment categories charted below, "Space Rental or Facility Fees" is the largest at $41.6K across 20 transactions, 2.6% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Space Rental or Facility Fees" leads Veloxis Pharmaceuticals, Inc.'s 6-category general-payment breakdown at $41.6K, 2.6% of the reported total.

How Veloxis Pharmaceuticals, Inc. divides its payments

General-payment categories, ordered by reported total

1. Space Rental or Facility …$41.6K2. Food and Beverage$19.2K3. Honoraria$11.4K4. Consulting Fee$8.1K5. Education$7.8K6. Travel and Lodging$1.2K
Payment Type Amount Transactions
Space Rental or Facility Fees $41.6K 20
Food and Beverage $19.2K 633
Honoraria $11.4K 10
Consulting Fee $8.1K 2
Education $7.8K 98
Travel and Lodging $1.2K 3

Recipient Concentration in General Payments

The five largest recipient relationships account for $30,169.34 (33.8%) of $89,196.03 in this company's General Payments records across 537 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Veloxis Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Christina Klein$11.7KUniversity of Alabama Hospit…$5.0KHospital of the Univ of Penna$5.0KAlexander Wiseman$5.0KVanderbilt University Medica…$3.5K
  1. 1

    Christina Klein

    $11,700.85 across 11 reported transactions

  2. 2

    University of Alabama Hospital

    $5,000.00 across 1 reported transactions

  3. 3

    Hospital of the Univ of Penna

    $5,000.00 across 2 reported transactions

  4. 4

    Alexander Wiseman

    $4,968.49 across 6 reported transactions

  5. 5

    Vanderbilt University Medical Center

    $3,500.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $1.9K. Average per recipient: $2.1K.

Total Amount

$1,594,463.02

Avg per Transaction

$1.9K

Avg per Recipient

$2.1K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Veloxis Pharmaceuticals, Inc. Share

0.0%

#511 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Veloxis Pharmaceuticals, Inc.

Valneva Austria GMBH

$1.6M 1 recipients

Datascope Corp.

$1.6M 14 recipients

restor3d, inc.

$1.6M 1,071 recipients

Ethicon US, LLC

$1.6M 15,448 recipients

Grifols Shared Services North America, Inc.

$1.6M 138 recipients

Integrity Implants Inc. dba Accelus

$1.6M 1,045 recipients

Frequently Asked Questions

How much did Veloxis Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
Veloxis Pharmaceuticals, Inc. made $1,594,463.02 in payments to physicians and hospitals in Program Year 2024, across 822 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Veloxis Pharmaceuticals, Inc.? ▾
766 physicians and teaching hospitals received payments from Veloxis Pharmaceuticals, Inc. in 2024, averaging $2.1K per recipient.
What types of payments did Veloxis Pharmaceuticals, Inc. make? ▾
6 categories of general payment make up Veloxis Pharmaceuticals, Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Space Rental or Facility Fees" at $41.6K, representing 2.6% of the company's reported total.
How does Veloxis Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Veloxis Pharmaceuticals, Inc. ranks #511 by total payment amount.
What is the average payment size from Veloxis Pharmaceuticals, Inc.? ▾
Veloxis Pharmaceuticals, Inc.'s 822 transactions to 766 recipients in 2024 averaged $1.9K per transaction.
Where does the payment data for Veloxis Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Veloxis Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.